Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own0.40% Shs Outstand5.06M Perf Week3.00%
Market Cap15.53M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.04M Perf Month-16.69%
Income- PEG- EPS next Q- Inst Own5.62% Short Float / Ratio0.22% / 0.77 Perf Quarter-15.43%
Sales- P/S- EPS this Y- Inst Trans- Short Interest0.01M Perf Half Y-5.77%
Book/sh0.55 P/B5.59 EPS next Y- ROA- Target Price80.00 Perf Year-72.55%
Cash/sh1.42 P/C2.16 EPS next 5Y- ROE- 52W Range2.81 - 12.00 Perf YTD-67.33%
Dividend- P/FCF- EPS past 5Y37.59% ROI- 52W High-74.42% Beta1.13
Dividend %- Quick Ratio1.53 Sales past 5Y0.00% Gross Margin- 52W Low9.33% ATR0.30
Employees15 Current Ratio1.53 Sales Q/Q- Oper. Margin0.00% RSI (14)43.19 Volatility11.24% 9.85%
OptionableNo Debt/Eq0.00 EPS Q/Q15.04% Profit Margin- Rel Volume1.52 Prev Close3.33
ShortableYes LT Debt/Eq0.00 EarningsSep 29 BMO Payout- Avg Volume14.52K Price3.07
Recom1.00 SMA20-4.19% SMA50-11.37% SMA200-22.04% Volume22,082 Change-7.81%
Date Action Analyst Rating Change Price Target Change
Jan-04-19Upgrade B. Riley FBR Neutral → Buy $2.50 → $3
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17Upgrade William Blair Mkt Perform → Outperform
May-31-17Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17Reiterated Chardan Capital Markets Sell $6.50 → $5
Jul-11-16Initiated Chardan Capital Markets Sell $5
Dec-01-23 08:00AM
Nov-16-23 08:00AM
Nov-06-23 08:00AM
Oct-04-23 07:00AM
Oct-03-23 07:00AM
08:00AM Loading…
Sep-29-23 08:00AM
Sep-27-23 08:00AM
Sep-21-23 08:00AM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-21-23 02:01PM
Aug-18-23 08:00AM
Aug-15-23 08:00AM
Aug-02-23 08:00AM
Aug-01-23 07:30AM
08:00AM Loading…
Jul-27-23 08:00AM
Jul-19-23 08:00AM
Jul-13-23 08:00AM
Jul-11-23 08:00AM
Jul-06-23 08:00AM
Jul-05-23 08:00AM
May-16-23 04:05PM
May-01-23 08:00AM
Apr-25-23 04:15PM
Apr-19-23 02:01PM
Apr-14-23 08:00AM
Apr-11-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 09:09AM
08:00AM Loading…
Mar-29-23 08:00AM
Feb-21-23 08:00AM
Feb-15-23 08:00AM
Feb-13-23 08:00AM
Jan-04-23 08:00AM
Dec-01-22 08:00AM
Nov-22-22 08:00AM
Nov-10-22 08:00AM
Nov-09-22 08:00AM
Nov-08-22 03:40PM
Oct-31-22 08:00AM
Oct-28-22 04:30PM
Sep-27-22 08:00AM
Sep-22-22 08:00AM
Sep-12-22 08:00AM
Sep-08-22 06:48AM
Aug-01-22 08:00AM
Jul-29-22 09:36AM
Jul-28-22 08:00AM
Jul-20-22 06:00AM
Jul-07-22 08:00AM
Jun-13-22 07:00AM
May-19-22 04:05PM
May-16-22 06:00AM
May-11-22 07:00AM
May-10-22 07:00AM
May-09-22 07:00AM
Mar-21-22 08:00AM
Mar-09-22 07:30AM
Mar-08-22 11:45AM
Mar-05-22 07:02AM
Mar-02-22 07:00AM
Feb-28-22 09:12AM
Feb-11-22 07:00AM
Jan-26-22 08:30AM
Jan-19-22 08:30AM
Jan-04-22 07:00AM
Dec-30-21 11:03AM
Dec-05-21 06:13AM
Dec-03-21 07:45AM
Dec-01-21 08:30AM
Oct-26-21 08:00AM
Oct-25-21 08:30AM
Sep-22-21 09:00AM
Sep-10-21 08:30AM
Sep-07-21 07:00AM
Jul-07-21 09:15AM
Jun-29-21 04:01PM
Apr-28-21 10:25AM
Apr-22-21 07:30AM
Apr-20-21 06:40PM
Apr-12-21 12:48PM
Mar-04-21 08:30AM
Feb-25-21 01:41PM
Feb-01-21 11:26PM
Jan-06-21 09:32AM
Dec-11-20 09:00AM
Dec-03-20 10:00AM
Nov-30-20 11:35PM
Oct-27-20 09:00AM
Oct-06-20 08:30AM
Sep-29-20 09:30AM
Sep-10-20 08:00AM
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.